Background: In BCP-ALL, blinatumomab has demonstrated efficacy in two phase 2 trials: MT 103 -203 (Gökbuget et al, Blood 2017) in minimal residual disease (MRD) and MT 102 – 211 in relapsed/refractory (R/R) disease (Topp et al Lancet Oncology 2104). We describe the long-term outcomes after blinatumomab followed by HSCT. Methods: Survival after blinatumomab and HSCT in continuous complete remission (CCR) was evaluated. In the MRD trial, 116 patients between Nov 2010 and Feb 2014 were treated with blinatumomab; in the R/R trial, 189 patients between Jan 2012 and Oct 2013 were treated. Follow up in both trials continued through 2017. Results: Most patients with HSCT in CCR in the MRD trial were >35 yrs of age whereas those in the R/R trial were younger (Table). After follow up of at least 3 yrs in the MRD trial of patients ≤35 yrs, 16/26 (62%) were alive with HSCT vs 2/9 (22%) for non-HSCT; in patients >35 yrs, 19/48 (40%) and 13/27 (48%) were alive with HSCT and for non-HSCT, respectively. Median overall survival (OS) from HSCT was not reached in patients ≤35 yrs in either trial (Table). Conclusions: These results suggest that in transplant-eligible patients in CCR, HSCT following blinatumomab is a potential option. Clinical trial information: NCT01466179, NCT01207388

NE, not estimable. ^a 1 haploidentical. ^b 74 patients received on-study HSCT in CR; Ph+ and patients not in CR at treatment start excluded. ^c No VOD-related deaths. Study Sponsored by Amgen.